Clinical Trial Update: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase II/III study of the combination nivolumab, ipilimumab, and GM-CSF in patients with advanced cutaneous melanoma. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)
• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING